Tag Archives: Research and Development

Health Policy’s Gordian Knot: Rethinking Cost Control

The central, intractable obstacle to long-term cost containment is the near impossibility of saying “no” to ever-more-expensive care that yields small marginal benefits.

April 26, 2017

Global Vaccine Development: Lessons From The Road To A New HIV Vaccine Trial

This latest step in a global effort to develop an effective HIV vaccine builds on a legacy of failure, hubris, and reinvention. Each stage of this history has much to teach us about the development of preventive vaccines in general.

December 21, 2016

Why ‘Government Patent Use’ To Lower Drug Costs Won’t Stifle Innovation

Recent commentaries express concern about the impact of our proposal that the federal government consider using an existing law to negotiate or compel lower drug prices. We believe that the impact on innovation in fact would be minimal, and the results for society highly positive.

July 28, 2016

Government Appropriation Of Breakthrough Drug Patent Rights Would Deter Biopharmaceutical R&D And Innovation

Section 1498 allows the government eminent domain-type powers to circumvent an inventor’s patent exclusivity rights in exchange for “reasonable and entire compensation.” While some argue this could be used to drive down drug prices, however this may cause adverse consequences for R&D incentives...

June 20, 2016

Discovering New Medicines And New Ways To Pay For Them

With the growing importance of pharmaceuticals, Anthem and Eli Lilly identified two areas that we believe must be addressed in order to unleash a new wave of innovative approaches to pharmaceutical pricing.

January 29, 2016

From The Archives: Pharmaceutical Pricing

Welcome to “From the Archives,” a Health Affairs Blog series, where we take a timely topic and delve into the literature and history, from a Health Affairs angle, of course. Harvoni, Sovaldi, Repatha, Daraprim. Four drugs that have made news for how much they cost patients and insurers. But...

November 24, 2015

New Health Policy Brief: Antibiotic Resistance

A new policy brief from Health Affairs and the Robert Wood Johnson Foundation describes the repercussions of antibiotic resistance: when drugs have declining, limited, or no effectiveness in combatting certain bacterial infections.

May 22, 2015